Citations

Clear

9383 citation(s) found for "Thomas, PS".

Cardiac Output Response to Exercise in Relation to Metabolic Demand in Heart Failure with Preserved Ejection Fraction
Abudiab, Muaz M. , Redfield, Margaret M. , Melenovský, Vojtěch , Olson, Thomas P. , Johnson, Bruce D. , Kass, David A. , Borlaug, Barry A. , Melenovský, Vojtěch

Mayo Clinic

European Journal of Heart Failure | February 21, 2013 | Volume: 15 | Issue: 7 | Pages: 776-785

10.1093/eurjhf/hft026 | PMID 23426022 Get It

Abstract Aims Exercise intolerance is a hallmark of heart failure with preserved ejection fraction (HFpEF), yet its mechanisms remain unclear. The current study sought to determine whether increases in cardiac output (CO) during exercise are appropriately matched to metabolic demands in HFpEF. Methods and results Patients with HFpEF (n = 109) and controls (n = 73) exercised to volitional fatigue with simultaneous invasive (n = 96) or non-invasive (n = 86) haemodynamic assessment and expired gas analysis to determine oxygen consumption (VO2) during upright or supine exercise. At rest, HFpEF patients had higher LV filling pressures but similar heart rate, stroke volume, EF, and CO. During supine and upright exercise, HFpEF patients displayed lower peak VO2 coupled with blunted increases in heart rate, stroke volume, EF, and CO compared with controls. LV filling pressures increased dramatically in HFpEF patients, with secondary elevation in pulmonary artery pressures. Reduced peak VO2 in HFpEF patients was predominantly attributable to CO limitation, as the slope of the increase in CO relative to VO2 was 20% lower in HFpEF patients (5.9 ± 2.5 vs. 7.4 ± 2.6 L blood/L O2, P = 0.0005). While absolute increases in arterial–venous O2 difference with exercise were similar in HFpEF patients and controls, augmentation in arterial–venous O2 difference relative to VO2 was greater in HFpEF patients (8.9 ± 3.4 vs. 5.5 ± 2.0 min/dL, P < 0.0001). These differences were observed in the total cohort and when upright and supine exercise modalities were examined individually. Conclusion While diastolic dysfunction promotes congestion and pulmonary hypertension with stress in HFpEF, reduction in exercise capacity is predominantly related to inadequate CO relative to metabolic needs.
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Catalano, John, Deininger, Michael W. , Shields, Alan L. , Miller, Carole B., Silver, Richard T. , Talpaz, Moshe , Winton, Elliott F., Harvey, Jimmie H., Hare, Thomas, Erickson‐Viitanen, Susan, Sandor, Victor, Levy, Richard S., Kantarjian, Hagop M. , Verstovšek, Srđan , Mesa, Ruben A. , Gotlib, Jason , Gupta, Vikas , Sun, William , Verstovsek, Srdan , Talpaz, Moshe , Kantarjian, Hagop

Mayo Clinic

Journal of Clinical Oncology | February 20, 2013 | Volume: 31 | Issue: 10 | Pages: 1285-1292

10.1200/jco.2012.44.4489 | PMID 23423753 Get It

Purpose To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis. Patients and Methods COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment–I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis. Exploratory analyses were conducted on the following patient-reported outcomes (PROs) assessments: modified MFSAF v2.0 (individual symptoms and Total Symptom Score [TSS]), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and Patient Global Impression of Change (PGIC). Results Patients receiving ruxolitinib experienced improvements in individual myelofibrosis-related symptoms, although patients receiving placebo experienced worsening (P < .001). The majority (91%) of ruxolitinib-treated patients designated as ≥ 50% TSS responders (≥ 50% TSS improvement) self-reported their condition as either “Much improved” or “Very much improved” on the PGIC. These patients achieved significant improvements in the EORTC QLQ-C30 functional domains and Global Health Status/QoL versus patients receiving placebo, who experienced worsening on these measures (P ≤ .0135). Ruxolitinib-treated patients with a lesser degree of symptom improvement (< 50% TSS responders) also achieved improvements over placebo on these measures. The degree of spleen volume reduction with ruxolitinib correlated with improvements in TSS, PGIC, PROMIS Fatigue Scale, and EORTC Global Health Status/QoL. Ruxolitinib-treated patients who achieved a ≥ 35% reduction in spleen volume experienced the greatest improvements in these PROs. Conclusion Ruxolitinib-treated patients achieved clinically meaningful improvements in myelofibrosis-related symptoms and QoL, but patients receiving placebo reported worsening of symptoms and other PROs.
Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting
Wilson, Laura , Koch, Kenneth L. , Pasricha, Pankaj J. , Snape, William J., McCallum, Richard W. , Sarosiek, Irene , Farrugia, Gianrico , Calles, J. , Lee, L., Tonascia, James , Ünalp–Arida, Aynur , Hamilton, Frank A., Hasler, William L. , Parkman, Henry P. , Abell, Thomas L. , Nguyen, Linda Anh B.

Mayo Clinic

Neurogastroenterology & Motility | February 18, 2013 | Volume: 25 | Issue: 5 | Pages: 427

10.1111/nmo.12091 | PMID 23414452 Get It

AbstractBackgroundFactors associated with abdominal pain in gastroparesis are incompletely evaluated and comparisons of pain vs other symptoms are limited. This study related pain to clinical factors in gastroparesis and contrasted pain/discomfort‐ with nausea/vomiting‐predominant disease.MethodsClinical and scintigraphy data were compared in 393 patients from seven centers of the NIDDK Gastroparesis Clinical Research Consortium with moderate‐severe (Patient Assessment of Upper Gastrointestinal Disorders Symptoms [PAGI‐SYM] score ≥3) vs none‐mild (PAGI‐SYM < 3) upper abdominal pain and predominant pain/discomfort vs nausea/vomiting.Key ResultsUpper abdominal pain was moderate‐severe in 261 (66%). Pain/discomfort was predominant in 81 (21%); nausea/vomiting was predominant in 172 (44%). Moderate‐severe pain was more prevalent with idiopathic gastroparesis and with lack of infectious prodrome (P ≤ 0.05) and correlated with scores for nausea/vomiting, bloating, lower abdominal pain/discomfort, bowel disturbances, and opiate and antiemetic use (P < 0.05), but not gastric emptying or diabetic neuropathy or control. Gastroparesis severity, quality of life, and depression and anxiety were worse with moderate‐severe pain (P ≤ 0.008). Factors associated with moderate‐severe pain were similar in diabetic and idiopathic gastroparesis. Compared to predominant nausea/vomiting, predominant pain/discomfort was associated with impaired quality of life, greater opiate, and less antiemetic use (P < 0.01), but similar severity and gastric retention.Conclusions & InferencesModerate‐severe abdominal pain is prevalent in gastroparesis, impairs quality of life, and is associated with idiopathic etiology, lack of infectious prodrome, and opiate use. Pain is predominant in one fifth of gastroparetics. Predominant pain has at least as great an impact on disease severity and quality of life as predominant nausea/vomiting.
Embedding Concepts of Sex and Gender Health Differences into Medical Curricula
Miller, Virginia M. , Rice, Morrisa, Schiebinger, Londa , Jenkins, Marjorie , Werbinski, Janice L., Núñez, Ana E. , Wood, Susan F. , Viggiano, Thomas R., Shuster, Lynne T., Schiebinger, Londa

Mayo Clinic

Journal of Women's Health | February 15, 2013 | Volume: 22 | Issue: 3 | Pages: 194-202

10.1089/jwh.2012.4193 | PMID 23414074 Get It

Sex, a biological variable, and gender, a cultural variable, define the individual and affect all aspects of disease prevention, development, diagnosis, progression, and treatment. Sex and gender are essential elements of individualized medicine. However, medical education rarely considers such topics beyond the physiology of reproduction. To reduce health care disparities and to provide optimal, cost-effective medical care for individuals, concepts of sex and gender health need to become embedded into education and training of health professionals. In September 2012, Mayo Clinic hosted a 2-day workshop bringing together leading experts from 13 U.S. schools of medicine and schools of public health, Health Resources and Services Administration Office of Women's Health (HRSA OWH), the National Institutes of Health (NIH) Office of Research on Women's Health (ORWH), and the Canadian Institute of Health and Gender. The purpose of this workshop was to articulate the need to integrate sex- and gender-based content into medical education and training, to identify gaps in current medical curricula, to consider strategies to embed concepts of sex and gender health into health professional curricula, and to identify existing resources to facilitate and implement change. This report summarizes these proceedings, recommendations, and action items from the workshop.
Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review
Blumenfeld, Andrew , Napchan, Uri, Bender, Steven D. , Klein, Brad , Berliner, Randall, Schim, Jack , Friedman, Deborah I. , Young, William B. , Robertson, Carrie E. , Silberstein, Stephen D., Ashkenazi, Avi , Ailani, Jessica , Charleston, Larry , Dodick, David W. , Robbins, Matthew S. , Robertson, Carrie E , Friedman, Deborah I , Klein, Brad C

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 13, 2013 | Volume: 53 | Issue: 3 | Pages: 437-446

10.1111/head.12053 | PMID 23406160 Get It

Objective To describe a standardized methodology for the performance of peripheral nerve blocks ( PNB s) in the treatment of headache disorders. Background PNBs have long been employed in the management of headache disorders, but a wide variety of techniques are utilized in literature reports and clinical practice. Methods The A merican H eadache S ociety S pecial I nterest S ection for PNBs and other I nterventional P rocedures convened meetings during 2010‐2011 featuring formal discussions and agreements about the procedural details for occipital and trigeminal PNBs . A subcommittee then generated a narrative review detailing the methodology. Results PNB indications may include select primary headache disorders, secondary headache disorders, and cranial neuralgias. Special procedural considerations may be necessary in certain patient populations, including pregnancy, the elderly, anesthetic allergy, prior vasovagal attacks, an open skull defect, antiplatelet/anticoagulant use, and cosmetic concerns. PNBs described include greater occipital, lesser occipital, supratrochlear, supraorbital, and auriculotemporal injections. Technical success of the PNB should result in cutaneous anesthesia. Targeted clinical outcomes depend on the indication, and include relief of an acute headache attack, terminating a headache cycle, and transitioning out of a medication‐overuse pattern. Reinjection frequency is variable, depending on the indications and agents used, and the addition of corticosteroids may be most appropriate when treating cluster headache. Conclusions These recommendations from the A merican H eadache S ociety S pecial I nterest S ection for PNBs and other I nterventional P rocedures members for PNB methodology in headache disorder treatment are derived from the available literature and expert consensus. With the exception of cluster headache, there is a paucity of evidence, and further research may result in the revision of these recommendations to improve the outcome and safety of these interventions.
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma
Kourelis, Taxiarchis , Lacy, Martha Q. , Kyle, Robert A. , Kapoor, Prashant , Zeldenrust, Steven R., Hayman, Suzanne R. , Lust, John A., Russell, Stephen J. , Lin, Yi , Rajkumar, S. Vincent , Kumar, Shaji , Leung, Nelson , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Zent, Clive S. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | February 12, 2013 | Volume: 88 | Issue: 5 | Pages: 375-378

10.1002/ajh.23413 | PMID 23508840 Get It

To clarify the presentation and course of patients with chronic lymphocytic leukemia (CLL) and amyloidosis. Mayo databases were interrogated for patients who carried a diagnosis of amyloidosis and CLL evaluated at Mayo Clinic, Rochester from January 1974 to October 2012. Charts were abstracted and data analyzed. Of the 33 patients identified, 20 (61%) were diagnosed with AL and 13 (39%) with non‐AL. Only four patients had immunoglobulin light chain amyloidosis (AL) that could be solely attributed to the CLL clone; another six had both a plasma cell clone and a CLL clone that shared the same light chain. Median overall survival was 15.6 months for patients with AL and 58.1 months for patients with non‐AL. For patients with AL management involved chemotherapy targeted toward monoclonal plasma cells, lymphocytes or both, and for patients with non‐AL no specific amyloid treatment was administered. AL is a rare complication of CLL, but in this elderly population of patients non‐AL is nearly as common. Distinguishing between these two groups is essential since patients with non‐AL amyloidosis have better outcomes and they do not require cytotoxic chemotherapy to treat their amyloidosis. Am. J. Hematol. 88:375–378, 2013. © 2013 Wiley Periodicals, Inc.
Personhood and Embryo Adoption
Nelson, Thomas K.

Mayo Clinic

The Linacre Quarterly | February 7, 2013 | Volume: 79 | Issue: 3 | Pages: 261-274

10.1179/002436312804872767 | PMID 30082974 Get It

The morality of embryo adoption, or heterologous embryo transfer for rescue, remains controversial despite the issuance of Dignitas personae (2008). When evaluating such bioethical controversies, it is crucial to take account of the personal order. Personalism provides a fresh and heretofore underdeveloped perspective toward resolving this polarized issue in bioethics. I will argue that it is not discriminatory to oppose embryo adoption on the basis of the heterology between rescuer and embryo because the lack of genetic relatedness reflects a more profound lack of personal relatedness. The persons involved in embryo adoption are not meant for the bodily relationship of pregnancy because of the incommunicability of relationships that involve the total gift of the human body. From the perspective of biology, pregnancy is natural life support for the embryo. From the perspective of personhood, pregnancy is fundamentally a relationship of embodied persons, one that is irreplaceable and radically exclusive. The clinical implications of this analysis will be discussed.
Translational Medicine Individualizes Healthcare Discovery, Development and Delivery
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Biomarkers in Medicine | February 6, 2013 | Volume: 7 | Issue: 1 | Pages: 1-3

10.2217/bmm.13.1 | PMID 23387479 Get It

The Qdot-Labeled Actin Super-Resolution Motility Assay Measures Low-Duty Cycle Muscle Myosin Step Size
Wang, Yihua , Ajtai, Katalin , Burghardt, Thomas P.

Mayo Clinic

Biochemistry | February 5, 2013 | Volume: 52 | Issue: 9 | Pages: 1611-1621

10.1021/bi301702p | PMID 23383646 Get It